Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sino-Aluminas is a specialized biotechnology company headquartered in Beijing, China, that focuses on the research, development, and large-scale production of high-purity vaccine adjuvants. As a leading global supplier, the company provides a range of aluminum-based products, including aluminum hydroxide and aluminum phosphate gels, which are essential for enhancing the immunogenicity of human and veterinary vaccines. Sino-Aluminas operates under rigorous international Quality Management Systems and Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its components. Their adjuvants are widely utilized in vaccines targeting infectious diseases such as hepatitis, influenza, and COVID-19. Beyond manufacturing, the company offers technical consultancy and customized formulation services to assist pharmaceutical partners in optimizing vaccine stability and immune response. The company's expertise in particle size control and adsorption capacity makes it a critical partner in the global vaccine supply chain.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sino-Aluminas.